cause of the illness. The PCR for amplification of a 470-bp fragment of citrate synthase gene was performed according to a previously published protocol (5). DNA was extracted with QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany) from whole blood and the crust of the eschar collected on day 5 of illness. In addition, serum samples were tested by indirect immunofluorescent assay for specific IgG and IgM against Francisella tularensis and Rickettsia spp. (spotted fever and typhus group) 5 days and 10 weeks after onset of fever.

Diagnosis of ATBF was affirmed by positive PCR result from the crust of the eschar; further sequence analysis revealed the infection with R. africae. Serologic testing demonstrated seroconversion of IgG to R. conorii and R. rickettsii, which cross-reacts with R. africae (negative immunofluorescent assay IgG titer at initial testing and 1:1,024 for R. conorii and R. rickettsii 10 weeks later) (6). Thick and thin blood smears were negative for malaria.

ATBF is the second most well-established cause of febrile illness among travelers to sub-Saharan Africa, after malaria. Usually it manifests by fever (59%–100% of cases), headache (62%–83%), eschar (53%–100%), lymphadenopathy (43%–100%), and rash (15%–46%). The clinical and laboratory findings in the patient reported here were similar to those previously reported among R. afericae-infected patients (1). In the acute phase of illness, a biopsy and culture from an eschar, as well as PCR, are the most suitable methods to confirm the ATBF diagnosis. In this case, ATBF was proven by PCR and subsequent sequencing from a crust sample but not from whole blood and seroconversion of IgG.

The first information about R. africae in ticks in Uganda was published in 2013 by Lorusso et al. (7), but previously R. conorii also was found (8). The prevalence rate of R. africae infection among Amblyomma variegatum ticks in Uganda was 97.1% (9). Recently, Proboste et al. established the presence of previously undetected tickborne pathogens in rural dogs and associated ticks in Uganda. Tick species Haemaphysalis leachi, Rhipicephalus spp., and A. variegatum were infected by Rickettsia spp (18.9%), including R. conorii and R. massiliae; by Ehrlichia spp. (18.9%), including E. chaffeensis; and by Anaplasma platys (10).

Our MEDLINE literature search found no previous descriptions of human R. africae infection in Uganda. This case indicates that ATBF should be included as a possible diagnosis in persons with febrile illness who have traveled to Uganda, a well-known tourist destination.

References

Address for correspondence: Petra Bogovic, Department of Infectious Diseases, University Medical Center Ljubljana, Japljeva 2, 1525 Ljubljana, Slovenia; email: petra.bogovic@kclj.si

Polymyxin B Resistance in Carbapenem-Resistant Klebsiella pneumoniae, São Paulo, Brazil

Flávia Bartolletti, Bruna Mara Silva Seco, Carla Capuzzo dos Santos, Carolina Bragança Felipe, Mara Eliça Borsato Lemo, Tatiane da Silva Alves, Lilian F. Passadore, Marcelo J. Mimica, Suely Carlos Ferreira Sampaio, Alexandre Prehn Zavascki, Jorge Luiz Mello Sampaio

isolates, except those from urine.

Their genomic DNA macrorestriction profiles after isolates were identified by matrix- their genomic DNA macrorestriction profiles after isolates were detected during 2014–2015 and used as previously described (1ertapenem, meropenem, or imipenem) by disk-diffusion isolates that were nonsusceptible to at least 1 carbapenem according to EUCAST guidelines (2). Tigecycline and fosfomycin MICs were interpreted ac Testing) breakpoint for colistin in microbial drugs. Isolates with a MIC of 3 microdilution (3) for all other antimicrobial drug MICs, we used nonautomated broth microdilution (4) for PMB and tigecycline; the Etest (bioMérieux, Marcy l’Etoile, France) for fosfo- mycin; and the disk-diffusion method (4) for PMB, fosfomycin and polymyxins (5). Several outbreaks caused by carbapenem- and polymyxin-resistant Klebsiella pneumoniae (CPRKp) have been reported, mainly from Europe, and represent an emerging threat.

Carbapenem-resistant K. pneumoniae (CRKp) are endemic to Brazil, where polymyxin B (PMB) has been largely used against infections caused by these microorganisms. We evaluated PMB resistance rates and clonal diversity among CRKp isolates from patients in São Paulo, Brazil. The study was approved by the Research Review Board of Fleury Institute in São Paulo.

All K. pneumoniae isolates, except those from urine and active surveillance samples, recovered from inpatients during January 1, 2011–December 31, 2015, at 10 private tertiary-care hospitals in São Paulo were included in the study. K. pneumoniae isolates were identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; we analyzed only the first isolate from each patient, unless other isolates were recovered after a 90-day interval. To determine antimicrobial drug MICs, we used nonautomated broth microdilution (2) polystyrene plates with cation-adjusted Mueller–Hinton broth (Becton Dickinson, Franklin Lakes, NJ, USA) for PMB and tigecycline; the Etest (bioMérieux, Marcy l’Etoile, France) for fosfomycin; and the disk-diffusion method (3) for all other antimicrobial drugs. Isolates with a MIC of ≤2 mg/L for PMB were considered susceptible; this value is the EUCAST (European Committee on Antimicrobial Susceptibility Testing) breakpoint for colistin in Enterobacteriaceae (2). Tigecycline and fosfomycin MICs were interpreted according to EUCAST guidelines (2). Imipenem and meropenem MICs were determined using the Etest for all isolates that were nonsusceptible to at least 1 carbapenem (ertapenem, meropenem, or imipenem) by disk-diffusion (3). We phenotypically detected class A carbapenemases as previously described (4).

We used convenience sampling to select 62 CPRKp isolates that were detected during 2014–2015 and used pulsed-field gel electrophoresis (PFGE) to evaluate their genomic DNA macrorestriction profiles after XbaI digestion. Dice similarity indexes were calculated using the UPGMA method with 1.25% tolerance and optimization (5). The minimal Dice index for a clonal group was defined as 80%.

We performed multilocus sequence typing as described (http://bigsdb.web.pasteur.fr/klebsiella/klebsiella. html) for 11 isolates that represented the 2 major PFGE clonal groups, CPRKp1 and CPRKp2. The full bla_KPC nu- cleotide sequence was determined for these isolates (online Technical Appendix Table 1, http://wwwnc.cdc.gov/EID/ article/22/11-0695-Techapp1.pdf).

We included a total of 3,085 K. pneumoniae isolates in the analysis (online Technical Appendix Table 2). A significant increase in carbapenem resistance (p<0.001) was seen from 2011 (6.8%) to 2015 (35.5%) (Figure, panel A). During the last year of analysis, we detected K. pneumoniae carbapenemase (KPC) in 96.2% of CRKp isolates.

PMB MICs showed a bimodal distribution that was clearly differentiated by a 2 mg/L MIC (Figure, panel B). When we stratified MICs by year and carbapenem resistance, a significantly increasing trend of resistance was seen among CRKp isolates from 2011 (0%) to 2014 (24.8%) to 2015 (27.1%) (p<0.001) (Figure, panel C). Resistance among carbapenem-susceptible K. pneumoniae varied from 0.7% in 2011 to 3.9% in 2014 (p = 0.002).

We did not evaluate the mechanism of PMB resistance. However, this resistance in KPC-producing K. pneumoniae is probably caused by the loss of mgrB function or the presence of nonsynonymous substitutions in pmrB that upregulate the pmrCAB and arrBCADTEF-pmrE operons, resulting in modification of lipid A. All these genes are located on the bacterial chromosome. Susceptibility testing showed that amikacin and tigecycline were the most active non–β-lactam antimicrobial agents against CPRKp isolates (amikacin 73.8%, tigecycline 69.4%) and CRKp isolates (amikacin 79.9%, tigecycline 72.2%) (online Technical Appendix Table 3).

PFGE identified 2 major clonal groups. The largest group, CPRKp1 (n = 30), belonged to sequence type (ST) 11, and the other group, CPRKp2 (n = 17), belonged to ST437. Both STs belonged to clonal complex (CC) 258. Inter- and intrahospital dissemination among private and public hospitals was observed. All isolates tested had the bla_KPC-2 gene (online Technical Appendix Figure).

In a previous study, the PMB resistance rate was 27% among 22 CRKp isolates from patients at a tertiary hospital in São Paulo during 2008–2010 (6). This rate is much higher than the rate we obtained for 2010, possibly because the previous study had a small number of isolates. CPRKp has been reported in various European countries at rates similar to those we report (7).

The predominance of CC258 among KPC-2-producing K. pneumoniae, but not among CPRKp, was reported...
in Brazil (8), and ST11, a variant of ST258, has occasionally been detected in colistin-resistant KPC-producing isolates in Spain (9). The ST437 clone has been reported in KPC-2 producers in China (10), but we found no reports of CPRKp among this clonal group. Our findings show an alarming yearly increase in the rate of PMB resistance among CRKp isolates, mostly KPC-2 producing, and the occurrence of interhospital and intrahospital dissemination of CPRKp from CC258 in São Paulo.

This work was supported by a grant from the Fleury Institute, São Paulo, Brazil. F. Bartolleti was supported by a scholarship from the National Counsel of Technological and Scientific Development (CNPq).

References


Address for correspondence: Jorge Luiz Mello Sampaio, Faculdade de Ciências Farmacêuticas, Avenida Professor Lineu Prestes, 580, Butantã, São Paulo, SP, Brazil, 05508-900; email: sampaio@usp.br